Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine conjugate β-lyase is an enzyme activity found in various pyridoxal 5′-phosphate-dependent enzymes that can catalyze β-elimination of cysteine S-conjugates and selenocysteine Se-conjugates, generating reactive sulfur- or selenium-containing fragments, ammonia, and pyruvate[1][2][3][4]. In mammals, this activity is often not physiologically intended, but arises as a side reaction in aminotransferases and related enzymes[2][3]. The resulting metabolites can be excreted or, if chemically reactive, can cause cellular toxicity, including nephrotoxicity and carcinogenicity, through covalent modification of proteins and other macromolecules[2][3][4]. This metabolic pathway is particularly important for the activation and toxification of drugs, environmental pollutants, and naturally occurring compounds[2][3][4].
β-elimination of S-conjugated cysteine moieties resulting in formation of reactive intermediates; this can lead to drug bioactivation or toxification
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteine-S-conjugate beta-lyase.